Recursion Pharmaceuticals (RXRX) EPS (Weighted Average and Diluted) (2020 - 2025)
Historic EPS (Weighted Average and Diluted) for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$0.36.
- Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) fell 588.24% to -$0.36 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.84, marking a year-over-year decrease of 1870.97%. This contributed to the annual value of -$1.69 for FY2024, which is 701.99% down from last year.
- Per Recursion Pharmaceuticals' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.36 for Q3 2025, which was down 588.24% from -$0.41 recorded in Q2 2025.
- Recursion Pharmaceuticals' 5-year EPS (Weighted Average and Diluted) high stood at -$0.28 for Q3 2021, and its period low was -$1.33 during Q1 2021.
- In the last 5 years, Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of -$0.38 in 2022 and averaged -$0.44.
- Per our database at Business Quant, Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) tumbled by 5647.06% in 2021 and then skyrocketed by 7518.8% in 2022.
- Over the past 5 years, Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.39 in 2021, then increased by 23.08% to -$0.3 in 2022, then plummeted by 40.0% to -$0.42 in 2023, then plummeted by 55.34% to -$0.65 in 2024, then skyrocketed by 44.82% to -$0.36 in 2025.
- Its last three reported values are -$0.36 in Q3 2025, -$0.41 for Q2 2025, and -$0.5 during Q1 2025.